Fibromyalgia Clinical Trial
Official title:
A Prospective, Open-label, Study to Evaluate the Efficacy and Tolerability of the Food Supplement CELERGEN in Patients With Fibromyalgia
Celergén® is a dietary supplement with anti-inflammatory and antioxidant properties composed of marine sperm extract, hydrolyzed collagen, CoQ10, lutein and selenium. This is an open-label, prospective, study to evaluate the efficacy and tolerability of Celergen in 90 patients with Fibromyalgia. The study duration was 90 days and patients were evaluated by the: FIQ-R Fibromyalgia Impact Questionnaire Revised, Questionnaire of Health SF-12, Scale Clinical Global Impression Improvement assessed by the patient (PGI), and the Brief Pain Inventory (BPI). Blood samples were obtained at weeks 0 and 12 order for serum levels of Substance P and Tumor Necrosis Factor to measured blindly. Statistical analysis will be performed by analysis of variance for paired data.
Fibromyalgia Syndrome (FMS) is a disease characterized by chronic widespread pain, along with
muscle stiffness, sleep disorders, chronic fatigue, anxiety, depression, or neurocognitive
deficiencies and autoimmune dysfunction. FMS prevalence is about 2% of the general
population. Recently, a European study found a prevalence of 4.7% in all five countries
surveyed, including Spain. The etiology of FMS is still unknown, but recent evidence supports
the involvement of neuro-inflammation.
Celergén® is a dietary supplement with anti-inflammatory and antioxidant properties composed
of a proprietory mixture of herring and mackerel milt semen and sperm-filled reproductive
gland of male fish provided by Celergen Ltd, Luxemburg), hydrolyzed collagen, CoQ10, lutein
and selenium.
This is an open-label, prospective, study to evaluate the efficacy and tolerability of
Celergen in 90 patients with Fibromyalgia. The study duration was 90 days and patients were
evaluated by the following:
INSTRUMENTS OF ASSESSMENT:
- Fibromyalgia Impact Questionnaire Revised (FIQR): The most commonly used scale to assess
the severity and impact of fibromialgia.
- Brief Pain Inventory (BPI): Evaluates both pain intensity and interference with daily
activities. The validated Spanish version will be used.
- Questionnaire of Health SF-12: This questionnaire, shortened version of the SF-36
version, has shown strong correlation with the latter both in relation to the physical
and mental summary, presenting the advantage of its reduced complexity.
- Scale Clinical Global Impression Improvement assessed by the patient (PGI): A Likert
scale of 7 points ranging from 1 (much better) to 7 (very much worse). It is used in
most studies and clinical trials to assess the patients perception of the evolution of
the disease in relation to the prescribed treatment.
COURSE OF STUDY:
The total duration of the study will be 12 weeks. Visit 1 (Week -0). - A general medical
history, in which the possible diseases suffered by the patient and the medications they are
taking for treatment is recorded, which should not be changed during the study. Data relating
to previous or ongoing treatments (pharmacological or not) for FMS will also be collected.
The inclusion and exclusion criteria will be checked, informed consent will be obtained. and
blood will be drawn and stored at -80o C until the end of the study for biochemical analysis
and comparison with blood drawn at the end of the study.
Visit 2 (baseline). - FIQR and the SF-12 and BPI questionnaires will be completed.
Celergen® treatment, to be administered as an adjunct to medication the patient is taking. A
Celergen® capsule will be prescribed after breakfast, unmixed with taking other supplement or
medication.
Visit 3 (Week 1). The FIQ, the BIS, the SF-12 and PGI questionnaires will be completed.
Visit 4 (Week 4). - Supplement tolerability will be assessed by recording the occurrence of
adverse effects. The FIQ, the BIS, the SF-12 and PGI questionnaires will be completed.
Visit 5 (Week 8). - Supplement tolerability will be assessed by recording the occurrence of
any adverse effects. The FIQ, the BIS, the SF-12 and PGI questionnaires will be completed.
Visit 6 (Week 12). - The FIQ, the BIS, the PGI, the SF-12 and PGI questionnaires will be
completed. The end of the treatment will be recorded. Potential adverse reactions will be
also be recorded. Final blood samples will be drawn for biochemical analysis.
STATISTICAL ANALYSIS:
Both the primary variable (the change in the initial and final mean scores of FIQ) and other
quantitative variables (differences in mean scores on the BIS and SF-12) will be evaluated by
analysis of variance for paired data.
Adverse reactions and PGI will be analyzed using descriptive statistics.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A |